WO2001032702B1 - Molecular structure of rhd negative locus - Google Patents

Molecular structure of rhd negative locus

Info

Publication number
WO2001032702B1
WO2001032702B1 PCT/EP2000/010745 EP0010745W WO0132702B1 WO 2001032702 B1 WO2001032702 B1 WO 2001032702B1 EP 0010745 W EP0010745 W EP 0010745W WO 0132702 B1 WO0132702 B1 WO 0132702B1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
rhd
acid molecule
molecular structure
sample
Prior art date
Application number
PCT/EP2000/010745
Other languages
French (fr)
Other versions
WO2001032702A2 (en
WO2001032702A3 (en
WO2001032702A9 (en
Inventor
Willy A Flegel
Franz F Wagner
Original Assignee
Drk Blutspendedienst Bw
Willy A Flegel
Franz F Wagner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU11455/01A priority Critical patent/AU784319B2/en
Priority to EP00972884A priority patent/EP1226169B1/en
Priority to US10/129,580 priority patent/US9034573B1/en
Priority to CNB008177775A priority patent/CN100475842C/en
Priority to DE60033954T priority patent/DE60033954T2/en
Priority to JP2001535401A priority patent/JP4620920B2/en
Application filed by Drk Blutspendedienst Bw, Willy A Flegel, Franz F Wagner filed Critical Drk Blutspendedienst Bw
Publication of WO2001032702A2 publication Critical patent/WO2001032702A2/en
Publication of WO2001032702A9 publication Critical patent/WO2001032702A9/en
Publication of WO2001032702A3 publication Critical patent/WO2001032702A3/en
Publication of WO2001032702B1 publication Critical patent/WO2001032702B1/en
Priority to AU2006202359A priority patent/AU2006202359B2/en
Priority to US12/390,982 priority patent/US9217181B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Abstract

The present invention relates to a nucleic acid molecular structure representing the Rhesus genes locus comprising the RHD, SMP1 and RHCE genes and/or the Rhesus box(es), preferably the hybrid Rhesus box, the upstream Rhesus box and/or the downstream Rhesus box. Furthermore, the invention relates to a process for the specific detection of the common RHD negative haplotypes. The invention further relates to the detection of RHD positive haplotypes in D-negative individuals. Various mutations in the RHD gene have been identified that allow for the development of diagnostic tools. The invention also relates to oligonucleotides, that specifically hybridize to the hybrid box, preferably the breakpoint or breakpoint region or to the upstream and downstream Rhesus boxes. Additionally, the invention relates to kits comprising or employing the above recited compounds of the invention.

Claims

98AMENDED CLAIMS[received by the International Bureau on 10 December 2001 (10.12.01); original claims 1-100 replaced by amended claims 1-82 (12 pages)]
1. A nucleic acid molecula' struclure rapresenting the Rhesus gen-3S IOCUS comprising the RHD, SMF 1, and RHCt " genes arranged in 5' to 3' ord^r.
2. The nucleic acid molecjlar stiuctun of claim 1 further compriϊinα the upstream Rhesus box ani/or the downstream Rhesus box, the seq jence of which is shown in Figures 9 and 10.
3. The nucleic acid molecu ar structure of claim 1 or 2 representative of the common RHD negative hsplotypes.
4. A nucleic acid molecular ,' tructuro representing the upstream Rhesus box the sequence of which is shovτv in figure 9.
5. A nucleic acid molecular structure rep-esenting the downstream Rh^su., box the sequence of which is shown in figure 10.
6. The nucleic acid molecular structjre ol claim 1 representative of the :ommon RHD positive haplotypes.
7. The nucleic acid molecular structure of claim 1 derived from a sample comprising an RHD posi.ive haplotype that is serologically classified RhD negative.
8. The nucleic acid molecuar structure of claim 7 wherein said sample is selected from a Caucasian population.
99 The nucleic acid molecular structure of claim 7 or 8 comprising partial RHD- deletions or substitutions.
10. The nucleic acid molecular structure of claim 9 comprising delations or substitutions of RHD exor.s 3 to 7, or 4 to 7 giving rise to a CcddEe phenotype, or 1 to 9.
11. The nucleic acid molecular structure of claim 9 comprising an RHD-CE-D hybrid allele, which is representative of a Cdes haplotype but also occurs in other Rhesus haplotypes carrying a £ ' breakpoint region located in intron 3, the sequence of which beakpoint region is shown in Figure 12, and/oi a 5' breakpoint region located in intron 7, the sequence of which breakpoint rogion is shown in Figure 13, or oth breakpoint regions.
12. The nucleic acid molecular structure of claims 1 , 6, 7 or 8 comprising an RHD- CE(3-7)-D hybrid allele, an RhD-CE(4-7)-D hybrid allele giving πse to a CcddEe phenotype or an RHCE() -9)-D(10) hybrid allele.
13. The nucleic acid molecula- structure of claim 11 wherein the RHD-CE- D h/brid allele of claim 11 encodes a polypeptid having antigen C reactivity.
14. The nucleic acid molecul r structure ot any one of claims 6 to 8 or a nucleic acid molecule being derived from tie RHD gene comprising \ single nucleotide substitution within the coding region of the RHD gene or within a 5' or 3' splice site.
15. The nucleic acid molecular structure or a nucleic acid molecule of :laim 14 wherein said nucleotide si bstitution gives rise to a stop-codon at codoi 1(i.
16. The nucleic acid molecular structure or a nucleic acid molecule of aim 15 wherein said substitution cene gives rise to an RHD(\N16X) mutation. 100
17. The nucleic acid molecular structure or a nucleic acid molecule of claim 16 wherein said substitution is a G→A substitution at nucleotide position 48.
18. The nucleic acid molecular structure or a nucleic acid molecule of claim 14 wherein said nucleotide substitutiDn gives rise to a stop codon at codcn 330.
19. The nucleic acid molecular structure or a nucleic acid molecule of claim 18 wherein said substitution < lives rise to ε RHD(Y330X) mutation.
20. The nucleic acid molecular structure or a nucleic acid molecule of Dlaim 19 wherein said substitution is a C -5 G substitution at nucleotide position 985.
21. The nucleic acid molecul ar structure or a nucleic acid molecule of :laim 14 wherein said substitution (lives rise to ε missense mutation at codon 212.
22. The nucleic acid molecular structure or a nucleic acid molecule of :lai ι 21 wherein said substitution (lives rise to e RHD(G2l2\f) missense mutation.
23. The nucleic acid molecular structure or a nucleic acid molecule of ;laiιn 22 wherein said substitution i ; a G→T substitution at position 635.
24. The nucleic acid molecular structure or a nucleic acid molecule of ;laim 14 wherein said substitutior gives rise to a mutation within a 4-nucleotide sequence, a 6-nucleotide sequence ot an 8-nucieotide sequence compi ising the consensus splice site at the exon8/ιntron8 boundary.
25. The nucleic acid molecular structure or a nucleic acid molecule of laiιn 24 wherein said substitution c ive rise to a HD(G1153(+1)A) mutation.
26. The nucleic acid molecular structure or a nucleic acid molecule of laim 25 wherein said substitution is a substitution at the 5' splice site intron 8 from AGgt to AGat. 101
27. The nucleic acid molecular struclure or a nucleic acid molecule of any one of claims 15 to 26 correlating with a RhD negative phenotype.
28. The nucleic acid molecular structure or a nucleic acid molecule of claim 14 wherein said substitution gives rise to a mutation within a 4-nucle otide sequence, a 6-nucleotide sequence o ' an 8-nucleotide sequence comprising the consensus splice site at the exon3/ ntron3 boundary.
29. The nucleic acid molecul ar structure or a nucleic acid molecule of olaim 28 wherein said substitution (lives rise to ε RHD(G486(+1 )A) mutation.
30. The nucleic acid molecular structure or a nucleic acid molecule of laim 29 wherein said substitution is a substitution at the 5' splice site intron 3 from ACgt to ACat.
31. The nucleic acid molecular structure or a nucleic acid molecule of ;laim 14 wherein said substitutior gives rise to a mutation within a 4-nιιcleotide sequence, a 6-nucleotide sequence oi an 8-nucleotide sequence comprising the consensus splice site at the exon9/ιntron9 boundary.
32. The nucleic acid molecular structure or a nucleic acid molecule of laim 31 wherein said substitution c ives rise to a r?HD K409KJ mutation.
33. The nucleic acid molecular structure or a nucleic acid molecule of olaim 32 wherein said substitution is a substitution at the 5' splice site intron 9 from AGgt to AAgt.
34. The nucleic acid molecula ■ structure or a nucleic acid molecule of claims 28 to 33 correlating with a Derphenotype.
35. A process to specifically detect a RHD negative haplotype causod by a nonsense mutation, missense mutation, splice site mutation, partial dele tion, partial insertion, partial ir version or ε combination thereof within t ie RHD gene, which terminates or obliterates the expression of a protein product of the 102 RHD gene in a sample by utilizing the RHD, SMP1 genes and/or the upslream
Rhesus box and/or the cownstroam Rhesus box, the sequence of which is shown in Figures 9 and 1 or any structural feature or nucleotide seq jence or both of any one of claims 2 lo 34 oi combinations thereof with teohn ques known in the art, preferably by PCR-RF LP, PCR-SSP or long-range PCR.
36. A process to specifically detect a common RHD negative haplotype causod by a nonsense mutation, missense nutation, splice site mutation, partial delation, partial insertion, partial inversion or a combination thereof within I e RHD gene, which terminates or obliterates t e expression of a protein product of the RHD gene comprising the following ste DS:
(a) isolating the DNA from a b od sample or blood donor
(b) hybridizing at least two oppositely oriented primers under stringent conditions to the DMA so a.s to carry out a PCR
(c) amplifying the target sequence
(d) separating the amp ifrcatioi i products on a gel
(e) analyzing the amplioons
37. A process to specifically detect a RHD negative haplotype in a sample comprising the step of detecting any of the breakpoint regions meniionad in claim 11.
38. The process of claim 37 /herein said detection or assessment is effected by PCR-RFLP, PCR-SSP or long-rango PCR or by a probe specifically hybridizing to the breakpoint or b'eakpeint region depicted in Figure A or 5 or 12 or 13 or hybridizing lo the upstream or downstream Rhesus hox in a Southern blot analysis.
39. The process of claim 38 wherein said probe hybridizes to the breakpoint or breakpoint region depictec in Figure 4 or 5 or 12 or 13.
40. The process of claim 38 or 39 wheiein detection of said hybridisation is effected by Southern blot analysis, gel-electrophoresis, biochip-analysis, fluorescence or molecular weight determination. 103
41. A vector comprising the nucleic acid molecular structure or a nucleic acid molecule of any one of clε ims 'I to 34.
42. A vector comprising the nucleic acid molecular structure or a nucleic acid molecule of any one of clε ims 10 to 34
43. A non-human host transformed with tho vector of claim 41.
44. A non-human host transformed with tho vector of claim 42.
45. A method of producing a protein product of the RHD gene comprising cuHuring the host of claim 44 undei suitable conditions and isolating the Rhesus piotein produced.
46. A protein product of the RHD gene er coded by the nucleic acid molecule or structure of any one of cla rris 10 ιo 34 DΓ produced by the method of claim 45.
47. An oligonucleotide hybrid zing under e.tringent conditions to a portion of the nucleic acid molecular s ucture or tho nucleic acid molecule of an t one of claims 1 to 34 wherein said portion comprises said (missense) mutation or said stop codon or to the complementa y portion thereof.
48. An antibody or aptamer o phage specifically binding to the protein pioduct of the RHD gene of claim 47.
49. A method to simultaneous y detect the Dresence of RHDΨ and any of he RHD molecular structures of any one of cla ms 1 to 34 comprising hybrid zinπ the oligonucleotide of claim 4',' and a< leasi an other oligonucleotide hybridizing to a RHDΨ structure under stringent conditions to nucleic acid molecules comprised in the samp e obtained from a human and detecting said hybridization. 104
50. A method for testing for ihe presence of a nucleic acid molecule encoding a mutant Rhesus D antigen or of ε nucl ic acid molecule carrying a deletion of the RHD gene as characterized by the nucleic acid molecular struciure or a nucleic acid molecule of any one of claims 1 to 34 in a sample comprising hybridizing the oligonucleotide of claim 47 under stringent conditions to nucleic acid molecules comprised in the sample obtained from a human and detecting said hybridization.
51. The method of claim 5C lurther comprising digesting the product of said hybridization with a restriction endonuc lease and analyzing the product ol said digestion.
52. A method for testing simu taneously foi the presence of RHDΨ and any of the RHD molecular structures of any one of claims 1 to 34 in a sample compi ising determining the nucleic ac ic sequence of at least a portion of the nucleic acid molecular structure or nucleic acid molocule of any one of claims 1 to 34, said portion encoding said (missense) muta:ion, said stop codon or a breaκpomt of said hybrid gene and dete, mining of at east a portion of a RHDΨ structure.
53. A method for testing for the presence of a nucleic acid molecule encoding a mutant Rhesus D antigen or of a nucloic acid molecule carrying a deletion of the RHD gene as characterized oy tho nucleic acid molecular structure or a nucleic acid molecule of any on of claims 1 to 34 in a sample compi ising determining the nucleic acid sequence of at least a portion of the nucleic acid molecular structure or nuc etc acid molecule of any one of claims 1 to 34, said portion encoding said (missense) muta ion, said stop codon or a breakpoint of said hybrid gene.
54. The method of claim 53 farther comprising, prior to determining said nucleic acid sequence, amplifica ion of at least said portion of said nucleic acid molecule or structure.
55. A method for testing simultcineously fcr the presence of RHDΨ and any of the
RHD molecular structures of any one cf claims 1 to 34 in a sample comprising carrying out an amplificat on reaction jsing a set of primers that amplifies at least a portion of said secuence wherein at least one of the primers employed in said amplification read ion is; the oligonucleotide of claim 47 and at least a primer amplifying a RHD^i structure and analysing the amplified product(s ).
56. A method for testing for tne presence of a nucleic acid molecule encoding a mutant Rhesus D antigen or of a nucleic acid molecule carrying a deletion of the RHD gene as characterized by tie nucleic acid molecular structure or nucleic acid molecule of any one of claims 1 to 34 in a sample comprising carrying out an amplificat on reaction jsing a set of primers that amplifies at least a portion of said sequence wherein at least one of the primers employed in said amplification reaction is the oligonucleotide of claim 47.
57. The method of any one of claims 54 to 56 wherein said amplification is effected by or said amplification reaction is the polymerase chain reaction (PCR).
58. The method of claim 57 wherein said DCR is PCR-RFLP, PCR-SSP or ong- range PCR.
59. The method of any one of ciaims 54 to 58 wherein the molecular weicht of the amplification product is analyzed.
60. A method for testing for th 3 presence of the nucleic acid molecular structure or nucleic acid molecule of any one of claims 7 to 34 encoding RHD positive alleles comprising the following steps:
(a) isolating the DNA from a blood sample or blood donor;
(b) hybridizing at leas: two oppos tely oriented primers under stringent conditions to the DMA so as to carry out a PCR;
(c) amplifying the targe t sequence;
(d) separating the amp ification products on a gel; and
(e) analyzing the amplicons. 106
61. The method of claim 60 v 'herein said HD positive alleles are derived from a serologically RhD negativo sample.
62. The method of claim 60 or 61 wherein said sample is selectee from a Caucasian population.
63. A method for testing for tr e presence of a protein product of the RHL gene of claim 46 in a sample comprising assaying a sample obtained from a human for specific binding to the anti ody or aptamer or phage of claim 48.
64. A method for testing for tne presence of a protein product of the RHD gene encoding the nucleic acid molecular structure or nucleic acid molecule o any one of claims 7 to 34 ir a sample comprising utilizing direct agglutination methods, indirect antiglcbulin tests, monoclonal anti-D antibodies and/or adsorbtion/elution techniques.
65. The method of any one of claims 35 to 64 wherein said sample is blood, serum, plasma, fetal tissue, saliva, t rine, mucosal tissue, mucus, vaginal tissue, fetal tissue obtained from the vagina, skin, hair, hair follicle or an other human tissue,
66. The method of claim 65 ( ompris ng enrichment of fetal cells or extraction of fetal DNA or mRNA from maternal tissue, like peripheral blood, serum or plasma.
67. The method of any one of claims 35 to 66 wherein said nucleic acid molecule or proteinaceous material rom sad sample is fixed to a solid support.
68. The method of claim 67 wherein said solid support is a chip.
69. Use of the nucleic acid mc lecular strudure or the nucleic acid molecuie oi any one of claims 1 to 34 for the analysis of a negative or a positive Rhesus D phenotype. 107
70. A method for determining, hether a pεtient in need of a blood transfusiori is to be transfused with RhD negative blocd from a donor comprising the step of testing a sample from said patient for the presence of one or more nuole acid molecular structures or m cleic acid molecules of any one of claims 2 to !> and 7 to 34, wherein a pos tive te. ting for two different of said nuc eic acid molecular structures is ndicative of the need for a transfusion with Rh negative blood.
71. A method for determining whether blood of a donor is suitable for trεnsfusion to a patient in need thereof who should not be exposed to antigen C comprising the step of teuting a sample from said donor for the presence of the nucleic acid molecular structure of claim 11 wherein a positive testing for the nucleic acid molecular struct jre o claim 11 precludes the transrusion of the donor's blood.
72. A method for determining whether blood of a donor may be used for transfusion to a patient in ιeed thereof comprising the step of testing a sample from said donor for the presence of one or more nucleic acid molecular structures or nucleic acic molecules of any one of claims 1-34, wierβin a negative testing for the njcleic εicid molecular structure of claim 2-{» with or without a negative testing for one or more nucleic acid molecular structures or nucleic acid molecules of claim 7-34 excludes the transfusion of the donor's blood to a patient that is typed as RhD negative.
73. A method of assessing of the risk of a RhD negative mother of conceiving or carrying an RhD positive letus or of the risk of a mother having an anti-D titer of conceiving or carrying a fetus at ris k to develop hemolytic disease of the newborn comprising assessing a sample obtained from the father of ihe fetus for the presence of one or more nucle ic acid molecular structures o ' nucleic acid molecules as defined in any one ol claims 1 to 34.
74. The method of claim 73 v herein said nucleic acid molecular structure carries mutations or deletions. 108
75. A method for assessing the possibility or likelihood of a man being the father of a child by assaying a : sample obtained from said man for the presence of one or more nucleic acid molecular structures or nucleic acid molecules of any one of claims 1-34, wh rein the test results are used to determine the homozygosity for, the heierozygosity -or or the absence of any nucleic acid molecular structure or a nucleic molecule of claims 2-5 and 7-34 used to infer the possibility or likelihood of said man being the father of the child.
76. A method for treating a pregnan: woman being Rhesus D negative, wherein the foetus does not carry wo nucleic acid molecular structures or nucleic acid molecules of any one of claims 2 to 5 and 7 to 34 or is not homozygous for any nucleic acid molecule r structure o any one of claims 2 to 5 anc 7 lo 34 comprising administering anti D tc said woman.
77. Use of an aptamer, phage , monoclona antibody or a polyclonal antiserum as characterized in claim 48 or a preparation thereof for determination of the protein product of the RHD gene.
78. Use of claim 77 wherein said determination of the protein product of ihe RHD gene is effected in connecion with blood group typing.
79. A preparation comprising t e antibody or aptamer or phage of claims 48.
80. Kit comprising
(a) the oligonucleotide of claim 47; and/or
(b) the antibody of claim 48; and/or
(c) the aptamer of claim 48; and/or
(d) the phage of claim ^ 8; and/or
(e) a pair of primers us eful for carrying out the amplification reaction ol any one of claims 51 to 57.
81. A process to determine the presence of an antigen C encoded by a RHD gene comprising the step of detecting any of he breakpoint regions mentioned in claim 11. 109 A process to determine the presence o: an antigen C comprising the steps of the process of claim 37.
PCT/EP2000/010745 1999-11-02 2000-10-31 Molecular structure of rhd negative locus WO2001032702A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP00972884A EP1226169B1 (en) 1999-11-02 2000-10-31 Molecular structure of rhd negative locus
US10/129,580 US9034573B1 (en) 1999-11-02 2000-10-31 Molecular structure of RHD negative
CNB008177775A CN100475842C (en) 1999-11-02 2000-10-31 Molecular structure of RHD negative genes locus
DE60033954T DE60033954T2 (en) 1999-11-02 2000-10-31 MOLECULAR STRUCTURE OF THE RHD-NEGATIVE GENESIS
JP2001535401A JP4620920B2 (en) 1999-11-02 2000-10-31 Molecular structure of RHD negative locus
AU11455/01A AU784319B2 (en) 1999-11-02 2000-10-31 Molecular structure of RHD negative locus
AU2006202359A AU2006202359B2 (en) 1999-11-02 2006-06-02 Molecular structure of RHD negative locus
US12/390,982 US9217181B2 (en) 1999-11-02 2009-02-23 Molecular structure of RHD negative

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99121686 1999-11-02
EP99121686.2 1999-11-02
EP00111696.1 2000-05-31
EP00111696 2000-05-31

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/129,580 A-371-Of-International US9034573B1 (en) 1999-11-02 2000-10-31 Molecular structure of RHD negative
US12/390,982 Division US9217181B2 (en) 1999-11-02 2009-02-23 Molecular structure of RHD negative

Publications (4)

Publication Number Publication Date
WO2001032702A2 WO2001032702A2 (en) 2001-05-10
WO2001032702A9 WO2001032702A9 (en) 2001-10-11
WO2001032702A3 WO2001032702A3 (en) 2002-02-28
WO2001032702B1 true WO2001032702B1 (en) 2002-03-28

Family

ID=26071006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/010745 WO2001032702A2 (en) 1999-11-02 2000-10-31 Molecular structure of rhd negative locus

Country Status (9)

Country Link
US (2) US9034573B1 (en)
EP (2) EP1780217B1 (en)
JP (1) JP4620920B2 (en)
CN (1) CN100475842C (en)
AT (2) ATE462722T1 (en)
AU (2) AU784319B2 (en)
DE (2) DE60044105D1 (en)
ES (2) ES2283324T3 (en)
WO (1) WO2001032702A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081621A2 (en) * 2000-04-20 2001-11-01 Adnagen Ag Method, diagnostic kit and microarray for determining the rhesus factor
US20080261205A1 (en) * 2004-02-06 2008-10-23 Canadian Blood Services Method for the Simultaneous Determination of Blood Group and Platelet Antigen Genotypes
CN1570148B (en) * 2004-03-25 2010-08-18 深圳市血液中心 Individual RHD gene zygote type detection PCR primer and detergent kit and detection method
AU2008213634B2 (en) 2007-02-08 2013-09-05 Sequenom, Inc. Nucleic acid-based tests for RhD typing, gender determination and nucleic acid quantification
CA2731086A1 (en) * 2008-07-18 2010-01-21 Wen-Hua Fan Non-invasive fetal rhd genotyping from maternal whole blood
US20110070590A1 (en) 2009-09-22 2011-03-24 Jan Rohozinski Primers and Methods for Determining RhD Zygosity
EP2721171A1 (en) 2011-06-17 2014-04-23 Progenika Biopharma, S.A. Discrimination of blood type variants
US9359643B2 (en) 2013-03-08 2016-06-07 Progenika Biopharma S.A. Discrimination of blood type variants
CN103966228B (en) * 2014-04-25 2015-12-09 无锡市第五人民医院 A kind of Rh blood group DEL type RHD93T > A allelotrope and detection method thereof
EP3545102B1 (en) 2016-11-23 2021-07-28 Gassner, Christoph Determination of the genotype underlying the s-s-u- phenotype of the mnss blood group system
TWI709188B (en) 2018-09-27 2020-11-01 財團法人工業技術研究院 Fusion-based classifier, classification method, and classification system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
WO1995006137A1 (en) 1993-08-27 1995-03-02 Australian Red Cross Society Detection of genes
US5654419A (en) * 1994-02-01 1997-08-05 The Regents Of The University Of California Fluorescent labels and their use in separations
CA2286303A1 (en) 1997-04-08 1998-10-15 Human Genome Sciences, Inc. 20 human secreted proteins
US7005276B1 (en) * 1998-01-23 2006-02-28 DRK Blutspendedienst Baden-Württember GGmbH Nucleic acid molecules correlated with the Rhesus weak D phenotype
EP1064302A1 (en) * 1998-03-20 2001-01-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays

Also Published As

Publication number Publication date
DE60033954D1 (en) 2007-04-26
ATE462722T1 (en) 2010-04-15
ES2342837T3 (en) 2010-07-15
AU2006202359B2 (en) 2008-11-06
WO2001032702A2 (en) 2001-05-10
ATE356828T1 (en) 2007-04-15
US20110172406A1 (en) 2011-07-14
AU784319B2 (en) 2006-03-09
AU2006202359A1 (en) 2006-06-29
JP2003513620A (en) 2003-04-15
DE60044105D1 (en) 2010-05-12
JP4620920B2 (en) 2011-01-26
CN1413219A (en) 2003-04-23
EP1226169A2 (en) 2002-07-31
US9217181B2 (en) 2015-12-22
WO2001032702A3 (en) 2002-02-28
EP1226169B1 (en) 2007-03-14
CN100475842C (en) 2009-04-08
US9034573B1 (en) 2015-05-19
EP1780217B1 (en) 2010-03-31
DE60033954T2 (en) 2008-04-17
AU1145501A (en) 2001-05-14
WO2001032702A9 (en) 2001-10-11
ES2283324T3 (en) 2007-11-01
EP1780217A1 (en) 2007-05-02

Similar Documents

Publication Publication Date Title
JP6634105B2 (en) Processes and compositions for methylation-based enrichment of fetal nucleic acids from maternal samples useful for non-invasive prenatal diagnosis
Scheffer et al. Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7‐year clinical experience
JP6513622B2 (en) Process and composition for methylation based enrichment of fetal nucleic acid from maternal sample useful for non-invasive prenatal diagnosis
AU2004217872B2 (en) Identification of fetal DNA and fetal cell markers in maternal plasma or serum
Papageorgiou et al. Non-invasive prenatal diagnosis of aneuploidies: new technologies and clinical applications
JP6603232B2 (en) Methods for monitoring, diagnosing, and screening for bladder cancer
WO2001032702B1 (en) Molecular structure of rhd negative locus
JP2003513620A5 (en)
AU2009208035B2 (en) Compositions and methods for detecting Juvenile Renal Dysplasia or calcium oxalate stones in dogs
JP4889258B2 (en) Method for determining resistance to the onset of bovine leukemia
Song et al. Non-invasive fetal ABO genotyping in maternal plasma using real-time PCR
Bingulac-Popović et al. Prenatal RHD genotyping in Croatia: preliminary results
CA2318486A1 (en) Novel nucleic acid molecules correlated with the rhesus weak d phenotype
JP7108281B2 (en) Method for Predicting Presence or Absence of Presence of Under-50-Onset Depression
Avent Fetal genotyping
US9989537B2 (en) Methods and tools for vel blood group typing
JP5936223B2 (en) Testing for exacerbation of chronic obstructive pulmonary disease
Pedini et al. Identification of an Alu-mediated 5.7-kb deletion of the LU gene in a pregnant Moroccan woman with anti-Lu3
CN117535402A (en) Application of FRMPD4 gene mutant as detection target, detection reagent with FRMPD4 gene mutant and detection kit
Brunet et al. The Progress of Next Generation Sequencing in Preimplantation Genetic Testing
CN117487906A (en) GAMT gene mutant, reagent, kit and application
Grootkerk-Tax et al. Fragmented cell-free fetal DNA in the maternal circulation may hamper prenatal genotyping strategies; evaluation of a prenatal RHD genotyping strategy on cell-free plasma DNA
JPH06289013A (en) Method for judging platelet gene type using gene amplification method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 28/37-31/37, DRAWINGS, REPLACED BY NEW PAGES 28/37-31/37; AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
WWE Wipo information: entry into national phase

Ref document number: 2000972884

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 535401

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/004388

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 11455/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 008177775

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2000972884

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10129580

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2000972884

Country of ref document: EP